ADISO

ADS051 is a first-in-class, oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis that has completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year. Adiso is also developing ADS032, a first-in-class small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1) and is in advanced pre-clinical development for the treatment of respiratory and dermal inflammation... At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns... ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 - the innate immune system's receptors and first line sensors of pathogens and other danger signals. Chronic..

Primary location: Concord United States